A
TVTX icon

AlphaQuest’s Travere Therapeutics TVTX Stock Holding History

AlphaQuest’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,799
Closed -$260K – 1941
2025
Q4 		$260K Buy
6,799
+1,335
+24% +$43.4K 0.01% 1303
2025
Q3 		$131K Sell
5,464
-29,786
-84% -$560K 0.01% 1613
2025
Q2 		$522K Buy
35,250
+31,659
+882% +$525K 0.05% 578
2025
Q1 		$64.4K Buy
3,591
+47
+1% +$954 0.01% 1455
2024
Q4 		$61.7K Sell
3,544
-327
-8% -$5.78K 0.01% 1243
2024
Q3 		$54.2K Sell
3,871
-10,465
-73% -$109K ﹤0.01% 1395
2024
Q2 		$118K Buy
14,336
+10,127
+241% +$68.2K 0.02% 894
2024
Q1 		$32.5K Buy
4,209
+1,884
+81% +$15.9K 0.01% 981
2023
Q4 		$20.9K Buy
+2,325
New +$16.9K ﹤0.01% 961

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AlphaQuest's TVTX Position: Q1 2026 in Review

AlphaQuest sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 6,799 shares — an estimated $260K sold.

AlphaQuest first reported a position in TVTX in Q4 2023 and held it in 9 quarters. The position peaked at $522K in Q2 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • AlphaQuest reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 6,799 Travere Therapeutics shares in Q1 2026, an estimated $260K.
  • AlphaQuest first reported a position in Travere Therapeutics in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Travere Therapeutics position peaked at $522K in Q2 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.